SCHEMBL932471

SCHEMBL932471

Nc1cc(F)c(F)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
MAPT P10636 5/20 0.42
GAA P10253 5/20 0.42
KDM4E B2RXH2 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
PKM P14618 2/20 0.42
HSD17B10 Q99714 5/20 0.42
ALOX15 P16050 4/20 0.42
CYP3A4 P08684 2/20 0.42
ALOX12 P18054 3/20 0.39
HPGD P15428 2/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ADRB2 P07550 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
ADRA1A P35348 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12021951 0.86 ALDH1A1 (0.41) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL139113 0.80 CA6 (0.40) ALDH1A1MAPTKDM4EL3MBTL1HSD17B10
SCHEMBL24716192 0.79 ALDH1A1 (0.47) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL1129180 0.79 HSD17B10 (0.48) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL1946105 0.79 ALDH1A1 (0.43) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL741941 0.79 ALDH1A1 (0.37) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL11378722 0.79 ALDH1A1 (0.43) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL30193870 0.79 ALDH1A1 (0.37) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL12056456 0.79 ALDH1A1 (0.37) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL27728509 0.79 ALDH1A1 (0.37) ALDH1A1MAPTGAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704090-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-05-27 EP disclosed
EP-4735534-A2 BENZOTHIAZOLE DYES Detect, Inc. (US) 2026-05-06 EP disclosed
US-20260022122-A1 NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME CHECKMATE THERAPEUTICS INC. (KR) 2026-01-22 US disclosed
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 EP disclosed
EP-4619388-A1 CATHEPSIN L INHIBITORS Biofront Therapeutics (Beijing) Co., Ltd. (CN) 2025-09-24 EP disclosed
US-20250206707-A1 NOVEL COMPOUND INDUCING EXPRESSION OF ANTI-AGING GENE KLOTHO KLOTHO SCIENCES CO., LTD. (KR) 2025-06-26 US disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 CN disclosed
US-20250115619-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. 2025-04-10 US disclosed
US-12227520-B2 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use GILEAD SCIENCES, INC. (US) 2025-02-18 US disclosed
CN-119462659-A Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof 吉利德科学公司 2025-02-18 CN disclosed
US-7220738-B2 Rifamycin analogs and uses thereof ACTIVBIOTICS, INC. (US) 2007-05-22 US disclosed
EP-1773330-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2007-04-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed
EP-1767530-A1 BENZOXAZOLES KYOYU AGRI CO., LTD (JP) 2007-03-28 EP disclosed
EP-1697382-A2 RIFAMYCIN ANALOGS AND USES THEREOF ActivBiotics, Inc. (US) 2006-09-06 EP disclosed
WO-2006068904-A1 TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2006-06-29 WO disclosed
WO-2006014618-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2006-02-09 WO disclosed
US-20050209226-A1 Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one ACADIA PHARMACEUTICALS INC. 2005-09-22 US disclosed
WO-2005058231-A2 RIFAMYCIN ANALOGS AND USES THEREOF ACTIVBIOTICS, INC. (US) 2005-06-30 WO disclosed
US-20050137189-A1 Rifamycin analogs and uses thereof ACTIVBIOTICS PHARMA LLC 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115619-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE ZYX, CCNY, NCAPD3 ALDH1A1 1700/4885MAPT 1576/4885GAA 2473/4885
US-20050209226-A1 Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one CHRNA4, CHRNA2, CHRNA5 ALDH1A1 1911/4885MAPT 176/4885GAA 932/4885
US-12227520-B2 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use ZYX, CCNY, XDH ALDH1A1 1782/4885MAPT 1709/4885GAA 2501/4885
US-20250206707-A1 NOVEL COMPOUND INDUCING EXPRESSION OF ANTI-AGING GENE KLOTHO CTSA, ALDH1A2, KLHL20 ALDH1A1 537/4885MAPT 2897/4885GAA 394/4885
US-20050137189-A1 Rifamycin analogs and uses thereof RIF1, HDAC5, HDAC4 ALDH1A1 873/4885MAPT 3678/4885GAA 219/4885
US-20260022122-A1 NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME NAMPT, NAPRT, NNT ALDH1A1 789/4885MAPT 1402/4885GAA 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.